IN THE NEWS & PRESS RELEASES
Conference: October 2018
NABE Tech Economics Conference (TEC)
Sponsor: National Association for Business Economics (NABE)
Topic: Applications of Machine Learning in Non-Tech Sectors
October 28-30, 2018
COEX, Seoul, South Korea
Conference: October 2018
AI Pharma Korea
Sponsor: Korea Pharmaceutical and Bio-Pharma Manufacturers Association(‘KPBMA’)
Topic: How to Use AI to Generate Novel Drug Candidates
October 15, 2018
COEX, Seoul, South Korea
Conference: October 2018
5th Annual Drug Discovery USA Congress
Title : Using Machine Learning To Identify New Targets For Fibrosis
October 11-12, 2018
San Diego, CA
Conference: October 2018
ISWC 2018 (2018 International Semantic Web Conference)
Title : Accelerating Drug Discovery in Rare and Complex Diseases
October 8-10, 2018
Monterey, CA
Conference: September 2018
Evolution Summit
Title : The Next Big Thing: Revolutionizing Drug Discovery
through Artificial Intelligence (AI)
September 24-26, 2018
Dallas, TX
Press Release: July 10, 2018
NuMedii Announces Strategic Research Collaboration with Two Leading Academic Research Institutions Utilizing Single-Cell Sequencing to Identify Precision Therapeutics for IPF
Press Release: June 20, 2018
NuMedii Expands Board of Directors and Scientific Advisory Board with the Addition of Two Oncology Experts
Applied AI – January, 2018
14 Healthcare AI Applications
Pulmonary Fibrosis News – January, 2018
NuMedii Advances IPF Personalized Medicine with New Advisory Board to Guide AI Approach
Medical Device and Diagnostic Industry (MD+DI) – January, 2018
Sifting Nuggets of Truth out of the AI Hooplah
MedCity News – January, 2018
Andy Slavitt: When it comes to AI, it is the best of times, worst of times story
Press Release: January 5, 2018
World’s Leading Lung Disease Experts Join NuMedii’s Idiopathic Pulmonary Fibrosis Advisory Board
WuXi AppTec – October, 2017
Inside Perspectives: NuMedii Banking on Artificial Intelligence to Expedite the Discovery of Effective New Medicines
PharmTech – September, 2017
Expediting the Discovery and Development of Drugs – Drug repurposing, repositioning, and rescue can be faster, cheaper, and target more diseases than traditional drug discovery approaches
Press Release: April 11, 2017
NuMedii, Inc. Announces New Partnership To Discover And Advance New Treatments For Idiopathic Pulmonary Fibrosis
The Scientist – January, 2017
Repurposing Existing Drugs for New Indications
SOCIAL MEDIA
Follow us on Twitter
Congratulations to our #IPF advisor @IPFdoc for the prestigious NIHR Research Professorship! #PrecisionMedicine #bigdata #translationalmedicine in #IPF https://t.co/wO11AZpAJO
Excited to announce our new collaboration in IPF using single cell sequencing with @KaminskiMed @YaleMed and Dr. Ivan Rosas @BrighamWomens! Deepening our discovery efforts with the aim of developing #precisiontherapies https://t.co/vD1CAypeRJ
We have strengthened our BoD with the addition of Dr. Athena Countouriotis and welcome new SAB member Dr. Zemin Zhang. Excited to have these two oncology experts join us! https://t.co/v8bqU8JZjR
Our CEO @biotechfounder highlights our collaboration with @3LakesPartners as "a model going forward for a lot of biotechs". Profiled in the @WSJ: https://t.co/wKZWGRNwcK
Join us on Facebook.
jpmorgan.metameetings.net
MENLO PARK, Calif., Jan. 8, 2018 /PRNewswire/ -- NuMedii, Inc. today announced the formation of an Idiopathic...
prnewswire.com
One company in the artificial intelligence (AI) space, Menlo Park, Calif.-based NuMedii, has been pioneering the use of big data, AI and systems biology since 2010 to accelerate the discovery of precision therapies to address high unmet medical needs. As a next generation biopharma company,...
wxpress-test.wuxiapptec.com
Atul Butte, who is helping to guide UCSF into a new era of computational science and medicine, has been named the Priscilla Chan and Mark Zuckerberg Distinguished Professor at UCSF.
ucsf.edu